Odonate Therapeutics, Inc. (ODT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ODT Stock Price Chart Interactive Chart >
ODT Price/Volume Stats
|Current price||$1.12||52-week high||$7.10|
|Prev. close||$1.17||52-week low||$0.85|
|Day high||$1.20||Avg. volume||1,223,190|
|50-day MA||$1.82||Dividend yield||N/A|
|200-day MA||$2.95||Market Cap||43.11M|
Odonate Therapeutics, Inc. (ODT) Company Bio
Odonate Therapeutics, LLC develops therapeutics to enhance the lives of patients with cancer in the United States. It is developing Tesetaxel, a novel chemotherapy agent that has completed Phase II clinical trials for patients with advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
Most Popular Stories View All
ODT Latest News Stream
|Loading, please wait...|
ODT Latest Social Stream
View Full ODT Social Stream
Latest ODT News From Around the Web
Below are the latest news stories about Odonate Therapeutics Inc that investors may wish to consider to help them evaluate ODT as an investment opportunity.
NEW YORK, January 07, 2022--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspende
SHAREHOLDER ALERT: Morris Kandinov Investigating CORT, MTCH, LDI, and ODT; Shareholders are Encouraged to Contact the Firm
SAN DIEGO, Dec. 22, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Corcept Therapeutics, Inc., Match Group, Inc., Inc., loanDepot, Inc., and Odonate Therapeutics, Inc. If you are a current owner of shares of any of these stocks, contact [email protected] or call (619) 780-3993.
Odonate Therapeutics, Inc. (NASDAQ:ODT) was the target of a large growth in short interest in November. As of November 30th, there was short interest totalling 513,400 shares, a growth of 85.0% from the November 15th total of 277,500 shares. Based on an average trading volume of 604,900 shares, the short-interest ratio is currently 0.8 days. 
Insider Buying: Odonate Therapeutics, Inc. (NASDAQ:ODT) Major Shareholder Acquires $308,662.06 in Stock
Odonate Therapeutics, Inc. (NASDAQ:ODT) major shareholder Ecor1 Capital, Llc purchased 185,941 shares of the companys stock in a transaction dated Wednesday, December 1st. The stock was purchased at an average price of $1.66 per share, for a total transaction of $308,662.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, 
Assenagon Asset Management S.A. raised its holdings in shares of Odonate Therapeutics, Inc. (NASDAQ:ODT) by 543.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 346,296 shares of the companys stock after acquiring an additional 292,452 shares during the quarter. Assenagon Asset Management 
ODT Price Returns